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Abstract
Upon viral infections, pattern recognition receptors (PRRs) recognize pathogen-associated molecular patterns (PAMPs) and
stimulate an antiviral state associated with the production of type I interferons (IFNs) and inflammatory markers. Type I IFNs
play crucial roles in innate antiviral responses by inducing expression of interferon-stimulated genes and by activating
components of the adaptive immune system. Although pegylated IFNs have been used to treat hepatitis B and C virus
infections for decades, they exert substantial side effects that limit their use. Current efforts are directed toward the use of
PRR agonists as an alternative approach to elicit host antiviral responses in a manner similar to that achieved in a natural
infection. RIG-I is a cytosolic PRR that recognizes 59 triphosphate (59ppp)-containing RNA ligands. Due to its ubiquitous
expression profile, induction of the RIG-I pathway provides a promising platform for the development of novel antiviral
agents and vaccine adjuvants. In this study, we investigated whether structured RNA elements in the genome of
coxsackievirus B3 (CVB3), a picornavirus that is recognized by MDA5 during infection, could activate RIG-I when supplied
with 59ppp. We show here that a 59ppp-containing cloverleaf (CL) RNA structure is a potent RIG-I inducer that elicits an
extensive antiviral response that includes induction of classical interferon-stimulated genes, as well as type III IFNs and
proinflammatory cytokines and chemokines. In addition, we show that prophylactic treatment with CVB3 CL provides
protection against various viral infections including dengue virus, vesicular stomatitis virus and enterovirus 71,
demonstrating the antiviral efficacy of this RNA ligand.
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Introduction
Pathogen recognition is a key step in the initiation of the host
antiviral innate immune response. Specialized pattern recognition
receptors (PRRs) such as Toll-like receptors (TLRs) and RIG-I-like
receptors (RLRs) detect evolutionarily conserved structures known
as pathogen-associated molecular patterns (PAMPs) and initiate an
antiviral response. TLRs detect various PAMPs commonly found
in both bacteria and viruses, such as lipopolysaccharides (LPS),
and non-methylated CpG-containing DNAs (reviewed in [1]).
Although TLRs are highly important in pathogen recognition,
these receptors are mostly found at the cell surface and/or
endosomes in specialized cell types (e.g. dendritic cells and
macrophages). RLRs are cytosolic sensors present in virtually all
nucleated cells, and thereby sense intracellular pathogens at the
site of infection [2]. RIG-I, a well-studied RLR, specializes in
recognizing dsRNAs containing 59 triphosphate (59ppp) groups
(reviewed in [3]). Upon ligand engagement, RIG-I interacts with
the mitochondrial adaptor molecule MAVS (also called IPS-1),
which, in turn, interacts with TANK-binding kinase 1 (TBK1) and
IkB kinase (IKK) complexes, leading to the activation of IRF3 and
NF-kB, respectively. These transcription factors then activate
transcription of type I interferons (IFNs) and many pro-inflam-
matory cytokine genes [2].
Type I IFNs play essential roles in combating viral infections by
inducing expression of hundreds of interferon-stimulated genes
(ISGs), which together establish an antiviral state in cells [2]. In
addition, type I IFNs can activate components of the adaptive
immune system such as natural killer cells and dendritic cells, and
thereby orchestrate the emergence of the adaptive antiviral
response [4,5]. The efficacy of type I IFNs against viral infections
has not only be shown at the molecular level in the laboratory but
has also been demonstrated in the clinic, where pegylated IFN-a
has been used extensively as a therapeutic to treat infections of
hepatitis B and C viruses [6,7]. However, clinical efficacy is
accompanied by severe side effects such as nausea, hematological
toxicity and depression [8], symptoms that lower the quality of life
of recipients and also hamper adherence.
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Recently, major efforts have been directed to the use of PRR
agonists as antiviral agents. A TLR9 agonist, CpG oligodeox-
ynucleotides, was shown to prevent coxsackievirus B3 (CVB3)-
induced myocarditis [9]. Pretreatment with polyinosinic:polycy-
tidylic acid (poly(I:C)), a dsRNA mimic and ligand of TLR3 and
RLRs, suppressed Hendra virus infection [10]. Recently, RNA
ligands of RIG-I have also been reported to be highly immune
stimulatory: a short, 59ppp-containing RNA derived from the 39
UTR of foot-and-mouth disease virus was shown to be an efficient
type I IFNs inducer that protected against challenge viral
infections [11]; two 59ppp-containing RNA hairpins, both of
which effectively activated the RIG-I signaling pathway, were
shown to elicit protective antiviral immunity [12,13]. Employing a
systems analysis approach, Goulet et al. demonstrated that a VSV
hairpin induced an extensive, broad spectrum of RIG-I responsive
genes compared to the profile of interferon stimulated genes (ISGs)
induced by recombinant type I IFNs, thus providing a more
complete and balanced immune activation [13]. Together, these
results indicate that RIG-I agonist may be promising candidates as
antiviral agents.
From in vitro studies, it is known that RIG-I activation requires
short double-stranded RNAs containing an intact 59ppp group
[14,15]. A number of viral RNA species have been reported to
activate RIG-I, including the well-known panhandle RNA
structures of many negative-strand RNA viruses [2]. In addition,
59ppp-containing in vitro transcripts of the Epstein–Barr virus
(EBV)-encoded small RNAs (EBERs) [16], the Leader transcript of
measles virus [17], and the polyU/UC tract from the 39 UTR of
hepatitis C virus (HCV) genome [18] have also been shown to
activate RIG-I. Remarkably, the secondary structures of these
RNA elements vary considerably – the panhandle RNAs are
hairpin-shaped, containing a short double-stranded stem and a
relatively large single-stranded loop [19], whereas the EBERs form
more complex structures involving multiple stems with bulges and
loops [20]; and the polyU/UC tract of HCV is, in fact, believed to
be a linear stretch of RNA [18]. These data indicate that the
recognition of RNA structures by RIG-I is perhaps more complex
than currently understood.
Picornaviruses do not produce 59ppp-containing RNA species
during infection, and are known to activate MDA5, but not RIG-I,
through its double-stranded replication intermediate [21]. How-
ever, picornavirus genomic RNA contains several well-studied,
stable RNA structures that could potentially serve as potent RIG-I
ligands when artificially provided with 59 ppp moiety. In this
study, we investigated whether any of these structured RNA
elements, when provided with 59ppp by in vitro transcription,
would activate RIG-I signaling and the antiviral response. We
demonstrate that a coxsackievirus B3 (CVB3) cloverleaf containing
a 59ppp moiety stimulated the RIG-I pathway, but other RNA
stem-loop structures of similar lengths only poorly activated RIG-
I, demonstrating the complexity and specificity of ligand
recognition by this receptor. These results contribute to the
identification and characterization of RIG-I ligands as potential
antiviral agents.
Results
T7 transcripts of the first 1000 nt of CVB3 sequence
activates RIG-I
Picornavirus genomic RNA contains several structured elements
including the cloverleaf structure (CL) at the extreme 59 terminus,
the stem-loop structures within the viral internal ribosomal entry
site (IRES), the cis-acting RNA element (CRE) and additional
stem-loop structures within the 39 UTR (Fig. 1A). To investigate
whether any of these RNA elements in the CVB3 genomic RNA
could stimulate RIG-I, we produced in vitro transcribed RNAs
(ivtRNAs) corresponding to 2 kb fragments of the CVB3 genomic
sequence with 1 kb overlaps, and investigated their individual
abilities to activate RIG-I by an IFN reporter assay. Quality and
concentrations of these transcripts were confirmed by gel
electrophoresis prior to transfection (data not shown). Upon
transfection in wt mouse embryonic fibroblasts (MEFs), ivtRNA
corresponding to nucleotide (nt) 1–2000 of CVB3 genome (CVB3
1–2000) induced significantly higher levels of IFN-b promoter
activation than all other segments of the genomic RNA (Fig. 1B).
When RNA transfection was carried out in RIG-I2/2 MEFs none
of the RNA fragments induced any significant IFN-b activation
(Fig. 1C), demonstrating that the responses observed in Fig. 1B
were indeed dependent on RIG-I.
To further refine the RNA element that activates RIG-I,
shorter, 1 kb, 59ppp-containing RNA fragments of CVB3 genomic
sequence were generated, and their RIG-I-stimulatory activities
were measured upon transfection into MEF cells. To demonstrate
the contribution of cytoplasmic RNA sensors RIG-I and MDA5,
transfections were performed in wt MEFs, as well as RIG-I2/2,
MDA52/2 and IPS-12/2 MEFs. All wt MEFs showed similar
patterns of IFN-b induction, and the first 1 kb (CVB3 1–1000) was
the most potent IFN-b inducer amongst all fragments tested
(Fig. 2A, 2C and 2E). The positive signals were completely
abolished in RIG-I2/2 and IPS-12/2 MEFs (Figs. 2D, 2F) but not
in MDA52/2 MEFs (Fig. 2B), indicating that RNA activity was
mediated by the RIG-I/IPS-1 signaling pathway.
To confirm that the first 1 kb of CVB3 sequence is truly the
RNA element recognized by RIG-I, ivtRNAs of different lengths
were produced, with or without the first 1000 nts of the genomic
sequence and assayed their abilities to activate RIG-I. Upon
transfection of all fragments including the first 1 kb and spanning
1–7 kb in total, we observed efficient activation of the IFN-b
promoter (Fig. 2G). However, when RNAs of the same length, but
lacking the first 1 kb sequence, were transfected into cells, only
background levels of IFN-b promoter activity were observed
(Fig. 2G). These results clearly demonstrate the importance of the
first 1 kb of CVB3 genomic sequence in activating RIG-I.
59ppp-containing CVB3 cloverleaf (CL) structure is a
potent RIG-I ligand
In addition to the 59ppp moiety present in all RNA fragments
tested so far, RIG-I also requires double-stranded regions for
recognition [3]. The first 1 kb of CVB3 genome contains the large
(nt 1–742) and highly structured 59 UTR (Fig. 1A), comprised of
several stem-loop structures (further referred to as Domains I
through VII), which were based on M-fold predictions as well as
extensive RNA probing experiments (reviewed in [22]). These
RNA elements are essential for viral translation and RNA
replication, and therefore, are structurally highly stable and
conserved among related viruses [23]. To test our hypothesis that
the 59 UTR is the main RIG-I-stimulating RNA sequence within
the first 1 kb of CVB3 sequence, we generated an ivtRNA
containing only nt 1–742 (59 UTR) of CVB3 and compared its
ability to activate RIG-I with that of nt 1–1000. Equimolar
amounts of RNAs were transfected because RIG-I is known to
bind to the termini of RNA ligands (i.e. in a 1:1 RIG-I:RNA
molecular ratio). Under these conditions, nt 1–742 induced IFN-b
promoter activation to the same extent as nt 1–1000 (Fig. 3A),
suggesting that the 59 UTR sequence is the main RNA element
that is recognized by RIG-I. This recognition is dependent on the
59ppp since treatment of 59 UTR with polyphosphatase, which
yields 59 monophosphate, or calf intestinal phosphatase, which
CVB3 Cloverleaf RNA Triggers an Antiviral Response
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yields 59 OH group, completely abolished IFN-b induction (data
not shown).
To further refine the RNA region with the highest potency of
RIG-I stimulation, we truncated the 59 UTR sequence from the 59
terminus, one stem-loop at a time, transfected equimolar amounts
of the resulting RNAs, and measured IFN-b response by reporter
assay. Surprisingly, loss of the first 100 nt of the 59 UTR, which
corresponds to the CL structure, almost completely abolished the
IFN-stimulatory activity of the RNAs (Fig. 3B), strongly implicat-
ing the CL as a potent RIG-I ligand. In line with this observation,
when ivtRNAs corresponding to each individual domain within
the 59 UTR (Fig. 3D) were transfected into cells, CL induced the
highest level of IFN-b activation (Fig. 3C).
Having established that the CL is a potent IFN-b inducer, we
set out to confirm that this response is truly dependent on RIG-I.
To this end we transfected RIG-I+/2 and RIG-I2/2 MEFs with
CL and determined IFN-b mRNA upregulation levels by RT-
qPCR. In addition, we also treated the CL RNA with Calf
Intestinal Phosphatase (CIP), which digests the 59ppp moiety that
is required for ssRNAs to activate RIG-I, and studied the resulting
RNA to activation IFN-b response in RIG-I+/2 and RIG-I2/2
MEFs. As shown in Fig. 3E, the CL RNA induced high levels of
IFN-b activation in RIG-I+/2, but not RIG-I2/2 MEFs, and CIP
treatment completely abolished the observed IFN-b response. To
assess whether CL-induced RIG-I activation is due to copy-back
species, which have been described as byproducts of T7
polymerase-produced RNAs [14,24], we analyzed this RNA
(before and after phosphatase treatment) on a denaturing gel. As
shown in Fig. 3F, only a single RNA species was present in our
RNA preparations, which corresponded to the expected size of
CL. This result also excludes that the lack of RIG-I activation by
the phosphatase-treated CL is due to degradation of this RNA
during treatment. Together, these results clearly identify CL as a
potent RIG-I ligand.
CVB3 CL induces potent IFN-a/b and ISG induction
We next sought to compare the antiviral activity of the CVB3
CL to that of the recently described short hairpin RNA derived
from VSV UTR sequences (Fig. 4A) that was identified as a potent
RIG-I agonist [13]. To confirm the lack of copy-back species in
the VSV hairpin preparation we also analyzed this RNA on
denaturing gel. As shown in Fig. 4A, both CVB3 CL and the VSV
hairpin migrated as single RNA bands of their expected sizes. In
comparison, a dsRNA control yielded two bands on denaturing
gel. Next, we transfected varying amounts of CL or VSV hairpin
RNA into A549 cells, and analyzed the phosphorylation status of
IRF3 at Serine 396, a marker of early activation and prerequisite
to RIG-I-mediated type I IFN induction. As shown by immuno-
blotting using an antibody specifically against S396 phosphorylat-
ed IRF3, both VSV hairpin and CVB3 CL led to equal levels of
IRF3 activation (Fig. 4B). We also assayed expression of several
IFN-stimulated genes (ISGs) including STAT1, RIG-I and ISG56
by immunoblotting, and found that the induction profiles of all
these proteins were identical upon transfection of equal amounts of
Figure 1. In vitro transcribed RNAs of the first 2 kb of CVB3 genome activates RIG-I. (A) Schematic representation of known RNA
structures in CVB3 genomic RNA. CL, cloverleaf. IRES, internal ribosomal entry site. CRE, cis-acting RNA element. Numbers refer to nucleotide positions
in the viral genomic RNA. (B, C) In vitro transcribed (ivt) RNAs with sequences corresponding to the indicated positions of CVB3 genomic RNA were
transfected into WT (B) or RIG-I2/2 (C) MEFs. IFN-b luciferase reporter assay was carried out 8 hours post transfection (hr.p.t.). Data presented as mean
+/2 SD.
doi:10.1371/journal.pone.0095927.g001
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Figure 2. ivtRNA of the first 1 kb of CVB3 genome activates RIG-I. ivtRNAs with sequences corresponding to the indicated positions of CVB3
genomic RNA were transfected into MEFs from MDA52/2 (B), RIG-I2/2 (D), IPS-I2/2 (F)mice or their WT litter controls (A, C, E). IFN-b luciferase reporter
assay was carried out 8 hr.p.t.. Data presented as mean +/2 standard deviation (SD). (G) ivtRNAs with sequences corresponding to the indicated
positions of CVB3 genomic RNA were transfected into WT or RIG-I2/2MEFs. IFN-b luciferase reporter assay was carried out 8 hr.p.t.. Data presented as
mean +/2 SD.
doi:10.1371/journal.pone.0095927.g002
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Figure 3. CVB3 Cloverleaf is a potent RIG-I agonist and protects against subsequent EV71 infection. (A, B) ivtRNAs with sequences
corresponding to the indicated positions of CVB3 genomic RNA were transfected into WT MEFs. IFN-b luciferase reporter assay was carried out
8 hr.p.t.. Data presented as mean +/2 SD. (C) ivtRNAs of individual domains in CVB3 59 UTR were transfected into WT MEFs. IFN-b luciferase reporter
assay was carried out 8 hr.p.t.. Data presented as mean +/2 SD. (D) Schematic representation of RNA ligands used in C. (E) CVB3 CL was mock-treated
CVB3 Cloverleaf RNA Triggers an Antiviral Response
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VSV hairpin or CVB3 CL (Fig. 4B). Furthermore, profiles of IFN-
b (Fig. 4C) as well as ISG56 (Fig. 4G) mRNA induction upon
transfection of these two RNA ligands were also similar. We also
compared the RIG-I-stimulatory activities of CVB3 CL and VSV
hairpin with a 59ppp-containing dsRNA of comparable size
(100 bp), which is also known to activate RIG-I [15,25]. All three
RNA species induced similar levels of RIG-I-mediated IFN-b
activation (Fig. S1).
CVB3 CL induces a broad-spectrum antiviral response
By employing the BioMark large-scale qRT-PCR analysis
platform, we also analyzed the cytokine and chemokine induction
profile of CVB3 CL as compared to that of VSV hairpin. As
shown in Fig. 5, the gene induction profiles by these two RNA
ligands were nearly identical for all genes analyzed. In addition to
classical ISGs such as CCL5 (RANTES), IFIT1/2, and IFITM1/
2, we also observed induction of type III IFNs (IL-28a, IL-28b,
and IL-29). In addition, proinflammatory cytokines and chemo-
kines including TNF-a, IL-1a/b and IL-6 were also efficiently
unregulated. Two inhibitors of IFN signaling, SOCS1 and 3 were
also induced upon transfection of CVB3 CL and VSV hairpin,
indicating that the negative feedback regulation of type I IFNs was
also activated. These results demonstrate that CVB3 CL activates
the RIG-I pathway as potently as VSV hairpin, an established
RIG-I ligand with a classical panhandle structure.
CVB3 CL treatment protects cells against challenge virus
infections
To further confirm the potency of CVB3 CL in triggering
antiviral immunity, we performed infections with dengue virus
(DENV) and VSV, in cells pre-treated with varying concentrations
of CVB3 CL or VSV hairpin. As shown in Fig. 6, both RNAs
provided protection against both viruses (Fig. 6A, B) at concen-
trations of 1 ng/ml and higher. This antiviral effect was not due to
cytotoxicity since no significant change in cell viability was
observed for either ligand at concentrations of up to 100 ng/ml
(data not shown). Together, these data convincingly demonstrate
that CVB3 CL is a potent immune stimulator and can effectively
induce an antiviral response in transfected cells.
Not all 59ppp stem-loop structures induced a RIG-I-mediated
type I IFN response (Fig. 3C), and we next asked whether the
observations with the IFN-b reporter assay were consistent with
the antiviral protection. To this end, HeLa cells were transfected
with various amounts of CL or Domain III, infected with
enterovirus 71 (EV71) 20 h later, and virus titers at 8 hours post
infection were determined by end-point titration. In mock-treated
as well as lipid alone-treated cells, EV71 infection led to high levels
of virus replication (Fig. 6C). Introduction of CL at 100 ng
reduced virus titer by approximately 100 fold, and this protective
effect was reduced with decreasing amounts of CL transfected
(Fig. 6C). Domain III did not protect cells against EV71 infection
even at the highest dose used (Fig. 6C), consistent with the earlier
observation that this RNA was a poor inducer of IFN-b promoter
activity (Fig. 3C).
Discussion
PRR ligands are currently being investigated as potential
antiviral agents. In this study, we examined several small,
structured RNAs derived from CVB3 sequence in their RIG-I-
stimulatory activities. Although none of these RNA ligands are
natural PAMPs during CVB3 infection, the CL structure, when
produced in vitro as a 59ppp-carrying RNA, proved a highly
potent RIG-I ligand. Upon transfection, CVB3 CL induces
expression of type I IFNs and type III IFNs, as well as many
proinflammatory cytokines and chemokines. This ligand protected
cells against various viral infections including EV71, DENV and
or treated with calf intestinal phosphatase (CIP), and transfected into RIG-I+/2 or RIG-I2/2 MEFs. IFN-b mRNA levels were determined at 8 hr.p.t.. Data
presented as mean +/2 SD. (F) RNAs used in E were analyzed on an 8 M Urea/8% Acrylamide gel, and visualized with SYBR Gold staining. RNA
fragments were transfected at equimolar amounts in each experiment.
doi:10.1371/journal.pone.0095927.g003
Figure 4. CVB3 CL activates IFN and ISG as efficiently as
published ligand. (A) CVB3 CL (with and without CIP treatment), VSV
hairpin and a short dsRNA control of 100 bp) were analyzed on an 8 M
Urea/8% Acrylamide gel, and visualized with SYBR Gold staining. (B)
A549 cells were transfected with indicated amounts of VSV short hairpin
RNA or CVB3 CL RNA. Cells were lysed at 24 hr.p.t. and subjected SDS-
PAGE analysis followed by immunoblotting using antibodies against
the indicated proteins. (C, D) A549 cells were transfected with 0.1, 1 or
10 ng/ml of VSV short hairpin RNA or CVB3 CL RNA and incubated for
24 hrs. Total RNA was isolated and subjected to qRT-PCR analysis using
primers specific for IFNb or ISG56 mRNAs. Data presented as mean +/2
SD.
doi:10.1371/journal.pone.0095927.g004
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VSV – completely unrelated viruses that exploit different host
factors and pathways for replication.
Another RIG-I agonist, a short hairpin derived from VSV
genome, was previously characterized as a potent immune
stimulator, capable of inducing ISG expression, similar to
recombinant type I IFNs, but also pro-inflammatory cytokines
such as TNF-a, IL-1a/b, IL-6, and CXCL10 as a result of NF-kB
activation. We compared the potency of this ligand and our CVB3
Figure 5. Gene induction profiles of CVB3 CL and VSV hairpin. A549 cells were transfected with indicated concentrations of CVB3 CL or VSV
hairpin for 24 hrs. Total RNA was isolated and subjected to qRT-PCR analysis using the BioMark system. Data presented as fold of induction in log10
scale as compared to mock-treated sample.
doi:10.1371/journal.pone.0095927.g005
CVB3 Cloverleaf RNA Triggers an Antiviral Response
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CL in both immune stimulation as well as functional antiviral
efficacy. Both ligands induced ISG and cytokine responses to
similar extents at the RNA and protein levels. Consistent with this
observation, both ligands fully protected cells against DENV and
VSV infections at the same concentration. Moreover, the VSV
hairpin was shown to protect mice against lethal influenza virus
infection [13]. Although not tested in this study, the fact that a
large number of cytokine and chemokine genes were induced to
nearly identical extents by CVB3 CL and VSV hairpin suggests
that CVB3 CL may also elicit protective antiviral immunity in vivo.
Altogether, our data demonstrate the reliability of utilizing RIG-I
pathway activation as a means of immune stimulation.
To date, most established RIG-I ligands, such as the panhandle
structure of negative-strand RNA viruses and 59ppp RNAs derived
from Sendai virus and VSV, all adopt a hairpin structure. In
comparison, our CVB3 CL adopts a rather unique structure,
forming in total 4 short stems, one of which contains a 3-nt bulge,
and 3 small loops. Interestingly, three other 59ppp-containing
RNA molecules tested in this study - Domains III, VI and VII -
completely failed to activate RIG-I. These RNAs are all predicted
to form hairpin structures, and contain 59ppp on blunt ends,
making them appear typical RIG-I ligands. Although Domains III,
VI and VII are smaller (54, 36 and 21 nt, respectively) than CVB3
CL (90 nt), they are still larger than some of the established
synthetic RIG-I ligands (reviewed in [3]), and Domain III (54 nt)
is, in fact, similar in size as the VSV hairpin tested in this study (67
nt). It has also been reported that the length of dsRNAs can play
an important role in determining RIG-I activation strength [15].
However, both Domain IV and VI have comparable or slightly
longer double-stranded stems than CVB3 CL, but did not induce
as much IFN-b as did CL. Of course, we cannot rule out that some
of these predicted structures do not fold into their predicted
structures, and therefore, poorly activate RIG-I. It is currently
difficult to pinpoint why Domains III, VI and VII were incapable
of inducing any detectable RIG-I activation, although these results
do suggest that ligand recognition by RIG-I may be more complex
than currently understood. These observations imply that identi-
fication of potent antiviral RIG-I ligands may require additional
fundamental investigation.
Known RIG-I ligands not only include 59ppp-containing
ssRNAs such as CVB3 CL and VSV hairpin, but also short
59ppp-containing dsRNAs [14,15,25]. One may ask whether one
type of RNA ligand is generally better than the other. We showed
that a 100 bp 59ppp dsRNA in vitro transcript induced similar level
of IFN-b response upon transfection as the CVB3 CL and the
VSV hairpin RNAs, suggesting that both single-stranded and
double-stranded ligands can be potent triggers of the RIG-I
signaling pathway. Also conceptually, it may not be particularly
beneficial to use single-stranded or double-stranded RIG-I ligands
to activation this pathway. With respect to large scale production
of RIG-I ligands (e.g. as a vaccine adjuvant or antiviral agent),
chemical synthesis of the 59ppp moiety is currently challenging. In
this regard, dsRNA ligands may be favorable since it has been
suggested 59ppp is not essential for RIG-I activation by dsRNAs
longer than 200 bp [15]. However, producing long dsRNAs in a
unified form in large quantities may also pose a technical
challenge. Research on exploiting RIG-I ligands as a means of
clinical intervention (as vaccine adjuvants or antiviral agents) is still
at its infancy. We know little about the in vivo safety profile,
delivery efficiency and potency of single-stranded or double-
stranded RIG-I ligands. Having a large repertoire of various RIG-
I-activating RNA molecules (as well as those that fail to do so) may
be very important to make better-informed decisions in the future.
Recombinant pegylated IFNs has been used as an antiviral
therapy against hepatitis B and C virus infections with tremendous
success, but with the price of prolonged severe side effects.
Therefore, efforts have been focused on the use of ligands of TLRs
and RLRs as inducers of antiviral immunity, because these
agonists likely mimic the earliest immune recognition events of a
natural antiviral response and induce a more extensive and
balanced immune activation. Because of the ubiquitous expression
profile of RIG-I, RNA agonists would be able to stimulate virtually
Figure 6. CVB3 CL protects cells against DENV and VSV
infections. (A) A549 cells transfected with 0.1, 1, 10 or 100 ng/ml
RNA constructs for 18 hrs prior to DENV challenge at MOI of 0.5. Cells
were fixed 24 hrs after infection and stained with an antibody against
the viral envelop (E) protein. DENV E+ cells were quantified and
presented as percentage of the total population. Data plotted as mean
+/2 SD. (B) A549 cells were transfected with 0.1, 1, 10 or 100 ng/ml RNA
constructs for 18 hrs prior to VSV-GFP challenge at MOI of 1. GFP-
positive cells were quantified at 24 hrs post infection and presented as
percentage of the total population. Data plotted as mean +/2 SD. (C)
HeLa cells were transfected with 1, 10 or 100 ng cloverleaf (CL) or
Domain III (DIII) and incubated for 16 hr. They were then infected with
enterovirus (EV) 71 at an MOI of 0.05 for 8 hrs. Virus titers were
determined by end point titration on HeLa cells. Data shown as mean
+/2 SD.
doi:10.1371/journal.pone.0095927.g006
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any cell type, including those at the site of infection. The
identification of a novel RIG-I agonist comprising the CVB3
cloverleaf will contribute to the development of RIG-I-based
antiviral agents. The identification of RNA ligands that possess all
the characteristics required for RIG-I induction - but fail to do so –
further demonstrates that there is much to learn about the
stimulation of the innate immune response by natural RNA
ligands.
Materials and Methods
In vitro synthesis of VSV hairpin and CVB3 ivtRNAs
The sequence of 59pppVSV hairpin RNA was derived from the
59 and 39 UTRs of the VSV genome as previously described
(Schlee 2009 Immunity) and in vitro transcribed RNA was prepared
as previously described (Goulet 2013 PLoS Pathogens). CVB3
ivtRNAs were produced by T7-driven in vitro transcription using
PCR products amplified the CVB3 infectious clone p53CB3/T7
[26]. 59pppRNAs were purified using Qiagen miRNA Mini Kit
(Qiagen) or by precipitation. Integrity and concentration of
purified RNA ligands were controlled by agarose gel electropho-
resis prior to each transfection experiment.
Cells culture and transfection
MEFs [27–29] and HeLa [21] cells were maintained in DMEM
supplemented with 10% FCS and 100 U/ml penicillin-strepto-
mycin, in a humidified incubator in the presence of 5% CO2.
A549 [30] cells were grown in F12K medium (ATCC) supple-
mented with 10% FBS and antibiotics. Lipofectamine RNAi Max
(Invitrogen) was used for transfection of 59pppRNAs according to
the manufacturer9s recommendations.
Viruses
Enterovirus 71 (strain BrCr) was produced on HeLa R19 cells
and titers determined by cytopathic effect-based end-point
titration. DENV (serotype 2 strain New Guinea C) was produced
on C6/36 cells and purified by ultracentrifugation through a 20%
sucrose cushion. DENV titers were determined by FACS upon E
protein staining on Vero cells (ATCC). VSV-GFP bearing the
methionine 51 deletion in the matrix protein was kindly provided
by J. Bell (Ottawa Health Research Institute, CA). Virus stocks
were grown on Vero cells, concentrated from cell-free superna-
tants by centrifugation at 15,000 rpm for 90 minutes at 4uC. Virus
concentration was determined by plague assay.
SDS-PAGE and immunobloting analysis. 59ppp-treated
cells were lysed in RIPA buffer (50 mN Tris-Hcl PH 8, 1%
sodium deoxycholate, 1% NP-40, 5 mM EDTA, 150 mM NaCl,
0.1% sodium dodecyl sulfate) and cleared by centrifugation at
17,0006g for 15 min at 4uC. Cleared lysates were subjected to
SDS-PAGE analysis on 4–20% acrylamide Mini-Protean TGX
precast gels (Biorad, Hercules, USA). Proteins were electropho-
retically transferred to Immobilon-PSQ PVDF membranes (Milli-
pore, Billerica, USA) and then subjected to immunoblotting using
indicated antibodies. Anti-pIRF3 Ser 396 and anti-RIG-I
antibodies were purchased from EMD Millipore, anti-IRF3 from
IBL, Japan, anti-IFIT1 from Thermo Fisher Scientific, anti
pSTAT1 Tyr701 and anti-STAT1 from Cell Signaling, and
anti-b-actin from Odyssey.
IFN-b luciferase reporter assay. IFN-b luciferase reporter
assay was performed as previously described [21]. Briefly,
approximately 200,000 cells were transfected with 50 ng pTK-
Rluc, which encodes renilla luciferase (Rluc) under the control of a
constitutively active promotor, and 250 ngpIFN-b-luc, which
codes for firefly luciferase (Fluc) under the control of the full
IFN-b promoter. 24 hours later cells were transfected with the
indicate amounts of RNA ligands and lysed 8 hrs post transfection
(hr.p.t.) in 16 passive lysis buffer (Promega). Luciferase activities
were measured using Dual Luciferase System (Promega) according
to menufacturer’s protocols. Fluc signal was first normalized
against Rluc signal, then against mock-transfected samples.
Differences were analyzed using student t-tests or one-way
ANOVA (Tukey’s Multiple Comparison Test). Throughout:
*, p,= 0.05; **, p,= 0.01; ***, p,= 0.001.
Real-time quantitative PCR. Real-time quantitative PCR
(RT-qPCR) was conducted as previously described [21].
Cell viability analysis. Cell surface expression of phospha-
tidylserine was measured using an APC-conjugated annexin V
antibody, as recommended by the manufacturer (Biolegend).
Briefly, specific annexin V binding was achieved by incubating
A549 cells in Annexin-V binding buffer (Becton Dickinson)
containing a saturating concentration of APC-annexin V antibody
and 7-amino-actinomycin D (7-AAD) (Becton Dickinson) for
15 min in the dark. APC-annexin V and 7-AAD binding to the
cells was analyzed by flow cytometry, as described previously using
an LSRII flow cytometer and FACS Diva software.
Fluidigm BioMark assay. Total RNA and cDNA were
prepared as described above. Intron-spanning PCR primers were
designed using Roche’s Universal Probe Library Assay Design
Center (www.universalprobelibrary.com) and obtained from the
Integrated DNA Technology company (Table S1). cDNA along
with the entire pool of primers were pre-amplified for 14 cycles
using TaqMan PreAmp Master Mix as recommended by
manufacturer’s protocol (Applied Biosystems). cDNA was treated
with Exonuclease I (New England Biolabs). cDNA samples were
prepared with 26 FastStart TaqMan Probe Master (Roche), GE
sample loading buffer (Fluidigm) and Taq Polymerase (Invitrogen).
Assays were prepared with 26 assay loading reagent (Fluidigm,
NY, USA), primers (IDT) and probes (Roche). Samples and assays
were loaded in their appropriate inlets on a 48.48 BioMark chip.
The chip was run on the Biomark HD System (Fluidigm, San
Francisco USA), which enabled quantitative measurement of up to
48 different mRNAs in 48 samples under identical reaction
conditions. Runs contained 40 cycles. Raw Ct values were
calculated by the real time PCR analysis software (Fluidigm) and
software-designated failed reactions were discarded from analysis.
All data are presented as a relative quantification with efficiency
correction based on the relative expression of target gene versus
the geomean of (GAPDH+Actin+b2 microglobulin) as the
invariant control. Fold of induction as compared to mock-treated
sample was plotted on a log10 scale and used to generate the heat
map. Statistical analyses were performed as described above.
Supporting Information
Figure S1 RNAs used in Fig. 4A were transfected into
RIG-I+/2 or RIG-I2/2 MEF cells at equimolar amounts.
Cells were harvested at 8 hrs post transfection. IFN-b mRNA level
in total RNA isolates was measured by RT-qPCR.
(DOCX)
Table S1 List of primers and probes used for high
throughput RT-q-PCR.
(DOCX)
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